These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49 related articles for article (PubMed ID: 9213002)
1. Effect of rhBMP-2 on the osteogenic potential of bone marrow stromal cells from an osteogenesis imperfecta mouse (oim). Balk ML; Bray J; Day C; Epperly M; Greenberger J; Evans CH; Niyibizi C Bone; 1997 Jul; 21(1):7-15. PubMed ID: 9213002 [TBL] [Abstract][Full Text] [Related]
2. rhBMP-2 induces terminal differentiation of human bone marrow mesenchymal stromal cells only by synergizing with other signals. Kathami N; Moreno-Vicente C; Martín P; Vergara-Arce JA; Ruiz-Hernández R; Gerovska D; Aransay AM; Araúzo-Bravo MJ; Camarero-Espinosa S; Abarrategi A Stem Cell Res Ther; 2024 Apr; 15(1):124. PubMed ID: 38679735 [TBL] [Abstract][Full Text] [Related]
3. Galunisertib downregulates mutant type I collagen expression and promotes MSCs osteogenesis in pediatric osteogenesis imperfecta. Infante A; Alcorta-Sevillano N; Macías I; Cabodevilla L; Medhat D; Lafaver B; Crawford TK; Phillips CL; Bueno AM; Sagastizabal B; Arroyo M; Campino A; Gerovska D; Araúzo-Bravo M; Gener B; Rodríguez CI Biomed Pharmacother; 2024 Jun; 175():116725. PubMed ID: 38744219 [TBL] [Abstract][Full Text] [Related]
4. Increased resorptive activity and accompanying morphological alterations in osteoclasts derived from the oim/oim mouse model of osteogenesis imperfecta. Zhang H; Doty SB; Hughes C; Dempster D; Camacho NP J Cell Biochem; 2007 Nov; 102(4):1011-20. PubMed ID: 17668424 [TBL] [Abstract][Full Text] [Related]
5. Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. Bargman R; Posham R; Boskey AL; DiCarlo E; Raggio C; Pleshko N Osteoporos Int; 2012 Mar; 23(3):1141-50. PubMed ID: 21901481 [TBL] [Abstract][Full Text] [Related]
6. Col1A-2 Mutation in Osteogenesis Imperfecta Mice Contributes to Long Bone Fragility by Modifying Cell-Matrix Organization. André G; Chretien A; Demoulin A; Beersaerts M; Docquier PL; Behets C Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069332 [TBL] [Abstract][Full Text] [Related]
7. A novel human TGF-β1 fusion protein in combination with rhBMP-2 increases chondro-osteogenic differentiation of bone marrow mesenchymal stem cells. Claros S; Rico-Llanos GA; Becerra J; Andrades JA Int J Mol Sci; 2014 Jun; 15(7):11255-74. PubMed ID: 24968268 [TBL] [Abstract][Full Text] [Related]
8. Dickkopf-1 (DKK1) blockade mitigates osteogenesis imperfecta (OI) related bone disease. Ko JY; Wang FS; Lian WS; Yang FS; Chen JW; Huang PH; Liao CY; Kuo SJ Mol Med; 2024 May; 30(1):66. PubMed ID: 38773377 [TBL] [Abstract][Full Text] [Related]
9. Upregulating CXCR4 in human fetal mesenchymal stem cells enhances engraftment and bone mechanics in a mouse model of osteogenesis imperfecta. Jones GN; Moschidou D; Lay K; Abdulrazzak H; Vanleene M; Shefelbine SJ; Polak J; de Coppi P; Fisk NM; Guillot PV Stem Cells Transl Med; 2012 Jan; 1(1):70-8. PubMed ID: 23197643 [TBL] [Abstract][Full Text] [Related]
10. Neurocranial growth in the OIM mouse model of osteogenesis imperfecta. Husain TS; Moore JC; Huston LA; Miller CA; Steele AT; Gonzales LA; Handler EK; Organ JM; Menegaz RA Anat Rec (Hoboken); 2024 Mar; 307(3):581-591. PubMed ID: 37638403 [TBL] [Abstract][Full Text] [Related]
15. Dental tissue changes in juvenile and adult mice with osteogenesis imperfecta. Moore JC; Husain TS; Huston LA; Steele AT; Organ JM; Gonzales LA; Menegaz RA; Handler EK Anat Rec (Hoboken); 2024 Mar; 307(3):600-610. PubMed ID: 37638385 [TBL] [Abstract][Full Text] [Related]
16. Structure-mechanics relationships of collagen fibrils in the osteogenesis imperfecta mouse model. Andriotis OG; Chang SW; Vanleene M; Howarth PH; Davies DE; Shefelbine SJ; Buehler MJ; Thurner PJ J R Soc Interface; 2015 Oct; 12(111):20150701. PubMed ID: 26468064 [TBL] [Abstract][Full Text] [Related]
17. Whole-Body Metabolism and the Musculoskeletal Impacts of Targeting Activin A and Myostatin in Severe Osteogenesis Imperfecta. Omosule CL; Joseph D; Weiler B; Gremminger VL; Silvey S; Lafaver BN; Jeong Y; Kleiner S; Phillips CL JBMR Plus; 2023 Jul; 7(7):e10753. PubMed ID: 37457877 [TBL] [Abstract][Full Text] [Related]
18. Craniofacial dysmorphism of osteogenesis imperfecta mouse and effect of cathepsin K knockout: Preliminary craniometry observations. Fosséprez J; Roels T; Manicourt D; Behets C Morphologie; 2024 Sep; 108(362):100785. PubMed ID: 38788496 [TBL] [Abstract][Full Text] [Related]
19. Schnurri-3 inhibition rescues skeletal fragility and vascular skeletal stem cell niche pathology in a mouse model of osteogenesis imperfecta. Xu R; Li N; Shi B; Li Z; Han J; Sun J; Yallowitz A; Bok S; Xiao S; Wu Z; Chen Y; Xu Y; Qin T; Lin Z; Zheng H; Shen R; Greenblatt M Res Sq; 2023 Jul; ():. PubMed ID: 37546916 [TBL] [Abstract][Full Text] [Related]
20. AAV-based gene editing of type 1 collagen mutation to treat osteogenesis imperfecta. Yang YS; Sato T; Chaugule S; Ma H; Xie J; Gao G; Shim JH Mol Ther Nucleic Acids; 2024 Mar; 35(1):102111. PubMed ID: 38261950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]